Purple Biotech Ltd Cash Flow Conversion Efficiency
Purple Biotech Ltd cash flow conversion efficiency. Based on the latest financial reports, Purple Biotech Ltd (KTOV) has a cash flow conversion efficiency ratio of -0.041x as of June 2020. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.32 Million ≈ $-6.22K USD) by net assets (ILA56.15 Million ≈ $150.52K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Purple Biotech Ltd (2013–2019)
Cash flow conversion efficiency of Purple Biotech Ltd from 2013 to 2019. This chart illustrates how Purple Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View KTOV live share price for real-time trading data and today's change.
Purple Biotech Ltd Cash Flow Conversion Ratio Explained
Purple Biotech Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Purple Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech Ltd ranked by their cash flow conversion efficiency. Also see how much is Purple Biotech Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Appili Therapeutics Inc
TO:APLI
|
0.018x |
|
MOVEBYBIKE EUROPE AB
F:6ZR
|
-7.892x |
|
Steakholder Foods Ltd
NASDAQ:STKH
|
-0.728x |
|
Christie Group plc
LSE:CTG
|
0.291x |
|
Valion Bio Inc
NASDAQ:VBIO
|
-0.444x |
|
Star Energy Group Plc
LSE:STAR
|
0.073x |
|
SECITS Holding AB (publ)
ST:SECI
|
0.666x |
|
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
|
-0.076x |
Annual Cash Flow Conversion Efficiency for Purple Biotech Ltd (2013–2019)
The table below shows the annual cash flow conversion efficiency of Purple Biotech Ltd from 2013 to 2019. Review Purple Biotech Ltd free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2019-12-31 | ILA10.86 Million ≈ $29.11K |
ILA-5.58 Million ≈ $-14.96K |
-0.514x | +33.31% |
| 2018-12-31 | ILA11.00 Million ≈ $29.50K |
ILA-8.48 Million ≈ $-22.73K |
-0.771x | +23.24% |
| 2017-12-31 | ILA8.59 Million ≈ $23.04K |
ILA-8.63 Million ≈ $-23.13K |
-1.004x | -114.60% |
| 2016-12-31 | ILA13.38 Million ≈ $35.88K |
ILA-6.26 Million ≈ $-16.79K |
-0.468x | -33.35% |
| 2015-12-31 | ILA9.43 Million ≈ $25.28K |
ILA-3.31 Million ≈ $-8.87K |
-0.351x | +93.40% |
| 2014-12-31 | ILA851.00K ≈ $2.28K |
ILA-4.53 Million ≈ $-12.13K |
-5.318x | -1082.67% |
| 2013-12-31 | ILA-946.00K ≈ $-2.54K |
ILA-512.00K ≈ $-1.37K |
0.541x | -- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more